Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144)
- 21 October 2026
- journal article
- Published by Wiley in Biotechnology and Bioengineering
Abstract
The successful translation of rationally designed HIV‐1 immunogens into effective vaccines requires manufacturing platforms that maintain structural conformity while meeting clinical‐grade quality standards. We developed and scaled up a robust, cGMP‐compliant process for N332‐GT5 gp140, a germline‐targeting envelope trimer designed to initiate broadly neutralizing antibody responses, which is now undergoing first‐in‐human evaluation in HVTN144. Starting with a stable CHO cell line developed using Leap‐In® transposon technology, we established a production clone exhibiting high‐titer expression (> 200 mg/L) and genetic stability through 60 population doublings. The manufacturing process scaled up efficiently from Ambr® 250 miniature bioreactors to 200‐L single‐use systems, delivering consistent product quality across multiple cGMP batches. A streamlined three‐step purification strategy—affinity capture, multimodal polishing, and viral clearance —yielded > 99% trimeric purity while preserving quaternary structure and native‐like antigenicity. Orthogonal LC‐MS analyses confirmed site‐specific glycan occupancy matching design specifications, while robust viral clearance exceeded 18‐log and 11‐log reductions for model retroviruses. Clinical material manufactured through this platform has been successfully administered in clinical trial HVTN144. This work establishes a scalable, reproducible manufacturing paradigm for structurally complex HIV‐1 envelope immunogens, advancing the field toward rational vaccine design based on germline‐targeting principles.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (5UM1 AI144462 03)
- Gates Family Foundation (INV‐070116)
This publication has 28 references indexed in Scilit:
- Scale-up and cGMP manufacturing of next-generation vaccine adjuvant saponin/MPLA nanoParticles (SMNP)Journal of Pharmaceutical Sciences, 2025
- DeGlyPHER: Highly sensitive site-specific analysis of N-linked glycans on proteins2022
- DeGlyPHER: An Ultrasensitive Method for the Analysis of Viral Spike N-GlycoformsAnalytical Chemistry, 2021
- Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidatesVaccine, 2021
- HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope StructureImmunity, 2018
- cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV‐1 envelope glycoprotein vaccine candidateBiotechnology and Bioengineering, 2017
- HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing AntibodiesImmunity, 2016
- ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificityJournal of Proteomics, 2015
- High‐throughput miniaturized bioreactors for cell culture process development: Reproducibility, scalability, and controlBiotechnology Progress, 2014
- Automated molecular microscopy: The new Leginon systemJournal of Structural Biology, 2005